Molecular basis of Japanese variants of pyrimidine 5'-nucleotidase deficiency

Hitoshi Kanno1, Takenori Takizawa, Shiro Miwa

  • 1Department of Transfusion Medicine and Cell Processing, Tokyo Women's Medical University, Tokyo, Japan. hikanno@clabo.twmu.ac.jp

Insights

Pyrimidine 5'-nucleotidase (P5N-I) deficiency is caused by novel mutations affecting erythroid maturation. These mutations impact substrate binding and protein stability, with one identified as a founder mutation.

Area of Science:

  • Biochemistry
  • Genetics
  • Hematology

Background:

  • Pyrimidine 5'-nucleotidase (P5N-I) is crucial for pyrimidine mononucleotide catabolism during red blood cell development.
  • Alternative splicing of P5N-I mRNA contributes to its functional diversity.
  • P5N-I deficiency leads to impaired erythroid maturation.

Purpose of the Study:

  • To identify genetic mutations responsible for P5N-I deficiency.
  • To investigate the functional consequences of identified P5N-I mutations on enzyme activity and stability.
  • To analyze the inheritance patterns and origins of specific mutations.

Main Methods:

  • Genetic analysis of nine families with P5N-I deficiency.
  • Identification and characterization of novel mutations (missense, splice, insertion, deletion).
  • In vitro expression studies in Cos-7 cells to assess mutant protein function and degradation pathways.

Main Results:

  • Five novel mutations in the P5N-I gene were identified in patients with P5N-I deficiency.
  • The G241R mutation (721C) demonstrated reduced affinity for cytidine monophosphate, indicating impaired substrate binding.
  • The L142P mutation (425C) resulted in accelerated protein degradation via the ubiquitin-proteasome pathway.
  • Haplotype analysis revealed the 721C mutation as a founder mutation in five unrelated families.

Conclusions:

  • Novel mutations in the P5N-I gene cause P5N-I deficiency, affecting erythroid maturation.
  • Specific mutations impact enzyme substrate binding and protein stability.
  • Understanding these mutations provides insights into the molecular basis of P5N-I deficiency and its inheritance.

Related Concept Videos

Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Transfer RNA Synthesis02:36

Transfer RNA Synthesis

One of the unique features of tRNA is the presence of modified bases. In some tRNAs, modified bases account for nearly 20% of the total bases in the molecule. Altogether, these unusual bases protect the tRNA from enzymatic degradation by RNases.
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Biosynthesis of Nucleic Acids01:28

Biosynthesis of Nucleic Acids

Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...